Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery
NCT05587205Phase 1Recruiting
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EO2002 in corneal endothelial cell loss (4 arms), sponsored by Asociación para Evitar la Ceguera en México. Primary endpoint: Safety and Tolerability of EO2002 at 26 weeks. Started Aug 2022; status: recruiting.
02
Drugs
EO2002
03
Conditions
corneal endothelial cell loss
Beyond the preview
Go deeper on NCT05587205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587205.